Amoxiclav (amoxicillin) Quicktab tablets 875 mg/125 mg. №14

active substances : amoxicillin, clavulanic acid;

1 tablet contains 875 mg of amoxicillin in the form of amoxicillin trihydrate and 125 mg of clavulanic acid in the form of a potassium salt;

excipients:  aspartame (E 951), silicon dioxide colloidal anhydrous, iron oxide yellow (E 172), “tropical mixture” flavoring, sweet orange flavoring, talc, hydrogenated castor oil, microcrystalline silicate cellulose.

Dispersible tablets.

Main physico-chemical properties:  yellow-brown speckled octagonal tablets with an aromatic smell.

Antibacterial agents for systemic use. ATX code J01C R02.

Amoxiclav (amoxicillin) Quicktab is a combination of amoxicillin, a penicillin antibiotic with a broad spectrum of antibacterial activity, and clavulanic acid, an irreversible beta-lactamase inhibitor, which forms an inactive complex with enzymes and protects amoxicillin from destruction. Clavulanate potassium has weak antibacterial activity and does not affect the mechanism of action of amoxicillin.

Because clavulanic acid inhibits beta-lactamases that normally inactivate amoxicillin, their combination is effective against many beta-lactamase-producing microorganisms resistant to amoxicillin.

The combination is active both  in  vitro and in the case of clinical infections against non-producing and penicillinase-producing gram-positive and gram-negative microorganisms : 

• Gram-positive aerobes: penicillin-sensitive strains of Streptococcus  pneumoniae ,  Streptococcus  pyogenes , methicillin-sensitive strains of  Staphylococcus  aureus ,  Listeria  spp .,  Enterococcus  faecalis ,  Enterococcus  faecium ,  Corynebacterium  spp .;
• gram-positive anaerobes: Peptococcus  spp .,  Peptostreptococcus  spp .,  Clostridium  perfringens ,  Actinomyces  israelli ;
• Gram-negative aerobes: Haemophillus  influenzae ,  Moraxella  catarrhalis ,  Escherichia  coli ,  Klebsiella  spp .,  Proteus  mirabilis ,  Proteus  vulgaris ,  Neisseria  gonorrhoeae ,  Neisseria  meningitid and s ,  Pasteurella  multocida ,  Salmonella  spp .,  Shigella  spp . ,  Vibrio  cholerae ,  Helicobacter  pylori ,  Bordetella pertussis ;
• Gram-negative anaerobes: Bacteroides  spp .,  Fusobacterium  spp .,  Prevotella  spp .

Pseudomonas  aeruginosa ,  methicillin-resistant strains of  Staphylococcus  aureus ,  Legionella  spp .,  Chlamydia  spp .,  Mycoplasma  spp. are resistant to the drug  .

The main pharmacokinetic properties of amoxicillin and clavulanic acid are similar. Both components are well absorbed after oral administration; food does not affect the degree of absorption. Maximum concentrations in blood serum are reached approximately 1-2 hours after taking the drug. Both components are characterized by a high volume of distribution in body fluids and tissues (lungs, middle ear exudate, maxillary sinus secretion, nasal sinus secretion, pleural and peritoneal fluid, prostate gland, tonsils, sputum, bronchial secretion, liver, gall bladder, uterus, ovaries, synovial fluid). Amoxicillin and clavulanic acid do not penetrate the blood-brain barrier in non-inflamed meninges.

Both components penetrate the placental barrier and are present in small amounts in breast milk.

Amoxicillin and clavulanic acid are characterized by low binding to blood plasma proteins.

Both components are excreted by the kidneys; amoxicillin is metabolized by 10-20%, and clavulanic acid by almost 50%. A small amount can be excreted through the intestines and lungs. The half-life of amoxicillin and clavulanic acid is 1-1.5 hours, increasing to 7.5 hours and 4.5 hours, respectively, in patients with severe renal impairment. Both substances are well removed by hemodialysis, but to a lesser extent by peritoneal dialysis.

Treatment of bacterial infections in adults and children caused by microorganisms sensitive to the combination of amoxicillin/clavulanic acid, such as:

• acute bacterial sinusitis;
• acute otitis media;
• confirmed exacerbation of chronic bronchitis;
• nosocomial pneumonia;
• cystitis;
• pyelonephritis;
• skin and soft tissue infections, including cellulitis, animal bites, severe dentoalveolar abscesses with widespread cellulitis;
• infections of bones and joints, including osteomyelitis

• Hypersensitivity to amoxicillin, clavulanic acid or other components of the drug; allergic reactions in history to any antibiotic of the penicillin series, infectious mononucleosis and lymphocytic leukemia.
• History of severe hypersensitivity reactions (including anaphylaxis) associated with the use of other beta-lactam agents (including cephalosporins, carbapenems or monobactams).
• A history of jaundice or liver dysfunction associated with the use of amoxicillin/clavulanate.